Item 2.02 Results of Operations and Financial Condition
On March 6, 2023, Inhibrx, Inc. (the “Company”) issued a press release
announcing its financial results for the year ended December 31, 2022. A copy of
the press release is furnished as Exhibit 99.1 to this report.
Item 7.01 Regulation FD Disclosure.
On March 6, 2023, the Company also posted an updated copy of its corporate slide
presentation to the “Investors” tab of its website at http://www.inhibrx.com. These
slides are also attached to this Current Report on Form 8-K as Exhibit 99.2. The
Company from time to time presents and/or distributes to the investment
community at various industry and other conferences slide presentations to
provide updates and summaries of its business. It undertakes no obligation to
update, supplement or amend the materials attached hereto as Exhibit 99.2.
The information in Items 2.02 and 7.01 of this Current Report on Form 8-K,
including Exhibits 99.1 and 99.2 attached hereto, is intended to be furnished
and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such
filing.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by Inhibrx, Inc. on March 6, 2023 99.2 Corporate Presentation
© Edgar Online, source Glimpses
postbrexitcompliance.com 